Since the beginning of 2023, it seems that Chinese-originated antibody-drug conjugates (ADCs) have suddenly sprinted from stealth mode into the spotlight on the global biopharma collaboration stage.
Although some domestic front-runners in the ADC field, such as RemeGen Ltd. and Kelun Biotech, have previously dominated headlines...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?